ADC Therapeutics goes public
Share this article
ADC Therapeutics chooses the New York Stock Exchange
On 15 May 2020, the Biopôle-based company, ADC Therapeutics went public. More than 14 million shares went for the price of $19. At the close of trading at the New York Stock Exchange, the share was worth $30, an increase of 57% in value since the opening.
The company’s was valued at around $1 billion. This operation has enabled the Swiss company to raise over $230 million to support its further development in anticancer drugs based on conjugated antibodies.